Circassia Pharmaceuticals Plc Block listing Interim Review (5783O)
May 18 2018 - 4:57AM
UK Regulatory
TIDMCIR
RNS Number : 5783O
Circassia Pharmaceuticals Plc
18 May 2018
18 May 2018
Circassia Pharmaceuticals plc
Block Listing Application
Circassia Pharmaceuticals plc ("Circassia" or "the Company")
today announces that an application (the "Application") has been
made to the UK Listing Authority and the London Stock Exchange for
a block listing of 400,000 ordinary shares of 0.08 pence each in
the Company ("Ordinary Shares") to be admitted to trading on the
Premium Segment of the London Stock Exchange.
The Application relates to Ordinary Shares to be issued from
time to time in order to satisfy the potential exercise of share
options granted under the 2015 Performance Share Plan Scheme.
It is expected that admission will become effective on 21 May
2018. When issued, the Ordinary Shares will rank pari passu with
the existing ordinary shares of the Company.
As at today, there are 333,466,262 ordinary shares in issue with
one voting right per share. The Company does not hold any shares in
treasury. The Company will notify on a monthly basis when there are
changes to the issued share capital of the Company, and these
monthly figures may be used by shareholders as the denominator for
the calculation by which they will determine if they are required
to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance
and Transparency Rules.
-Ends-
For further information, please contact:
Circassia Pharmaceuticals
plc
Julien Cotta, Company Tel: +44 (0) 1865 405
Secretary 560
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRGGUMAAUPRUBR
(END) Dow Jones Newswires
May 18, 2018 05:57 ET (09:57 GMT)
Circassia (LSE:CIR)
Historical Stock Chart
From Apr 2024 to May 2024
Circassia (LSE:CIR)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Circassia Group Plc (London Stock Exchange): 0 recent articles
More Circassia Pharmaceuticals News Articles